Starrex Management Cease-Trade Order Extended By Ontario

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Starrex Management Cease-Trade Order Extended By Ontario Securities Commission Pending Completion of Re-Filings

TORONTO, ONTARIO--(Marketwired - Jan. 12, 2016) - Starrex International Ltd. ("Starrex" or the "Company") (CNSX:STX) announces that, further to its news releases dated December 9, 23 and 31, 2015 regarding its intention to restate and re-file: (i) its first, second and third quarter unaudited interim financial statements for the periods ended March 31, June 30 and September 30, 2015; (ii) the corresponding management's discussions and analyses for the quarterly periods ended March 31, June 30 and September 30, 2015; and (iii) the management's discussion and analysis for the year ended December 31, 2014, and in accordance with the Company's application for a management cease-trade order pursuant to National Policy 12-203 pending completion of those re-statements and re-filings, the management cease-trade order issued on December 30, 2015 prohibiting the Company's Chief Executive Officer, Philip Garrett Clayton, and Chief Financial Officer, Deborah Ramiriz, from all trading in and all acquisitions of securities of Starrex for a period of 15 days was extended by the Ontario Securities Commission until two full business days following receipt by the Ontario Securities Commission of all filings which the Company is required to make under Ontario securities law or other order of the Director.

The Company intends to file the amended and restated interim financial statements, the corresponding management's discussions and analyses, and the management's discussion and analysis for the year ended December 31, 2014, as soon as is reasonably possible in accordance with the order issued by the Ontario Securities Commission.

This news release contains forward-looking information. All information other than statements of historical fact that address activities, events or developments that Starrex believes, expects or anticipates will or may occur in the future are forward-looking statements, including statements regarding the amended and restated quarterly unaudited financial statements and related management's discussions and analyses. This forward-looking information is subject to a variety of risks and uncertainties beyond Starrex's ability to control or predict that may cause actual events or results to differ materially from those described in such forward-looking information. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Starrex disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. Although Starrex believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be placed on this forward-looking information due to the inherent uncertainty thereof.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this press release.

Starrex International Ltd. Ronald Mann, Secretary, Chief Operating Officer and Investor Relations Officer (647) 981-2782 rmann@starrexintl.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Petco Investors: Important Call to Action Before Deadline

Updated Category News Views 159

Important Information for Petco Investors Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) has been a significant part of the investment landscape in recent times. Investors who purchased securities of Petco within a specified timeframe should take careful note of an important upcoming deadline that may impact their claims. The Rosen Law Firm, known for advocating...

Continue Reading
Vertafore Celebrates Major Industry Accolades for Innovation

Updated Category News Views 92

Vertafore's Recent Industry Recognitions Vertafore, a prominent name in the InsurTech landscape, has recently celebrated its inclusion on both the 2024 InsurTech100 list and the PropertyCasualty360 Insurance Luminaries Class of 2024, showcasing its dedication to innovation in the insurance sector. Recognition by InsurTech100 For the second consecutive year, Vertafore has...

Continue Reading
Rethinking the Value of a Four-Year College Degree Today

Updated Category News Views 242

Shifting Perceptions Around Higher Education In recent years, a significant change has occurred in the way many Americans view the value of higher education, particularly four-year college degrees. A recent survey indicates that nearly two-thirds of registered voters now believe that obtaining such a degree may not be worth the financial burden it often entails. Poll...

Continue Reading
Alkane Resources Q1 2026 Financial Performance Insights

Updated Category News Views 143

Alkane Resources Limited Announces Strong Q1 2026 Results Alkane Resources Limited (ASX: ALK, OTC: ALKEF, TSX: ALK) has shared remarkable financial results for the first quarter ending September 30, 2025. Following a recent merger with Mandalay Resources, the company has seen significant growth and progress. Key Highlights from Q1 2026 The condensed and consolidated...

Continue Reading
Spectral Medical Shares Updates on the Tigris Trial's Progress

Updated Category News Views 231

Spectral Medical Shares Updates on the Tigris Trial's Progress In a notable development, Spectral Medical Inc. (TSX: EDT), a company specializing in advanced therapeutics for sepsis and septic shock, has provided an important update regarding its Tigris trial. This Phase 3 study focuses on evaluating the efficacy of Polymyxin B Hemoperfusion (PMX) in treating adults...

Continue Reading